These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30168970)

  • 1. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VIII. Novel Drugs for Multiple Myeloma].
    Shibayama H
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1255-60. PubMed ID: 30168970
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drugs in the treatment of multiple myeloma].
    Oriol A; Motlló C
    Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
    Stegmann DA
    Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat (Farydak) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
    [No Abstract]   [Full Text] [Related]  

  • 7. Panobinostat approved for multiple myeloma.
    Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.
    Ocio EM; Dávila J; Caballero JC; Alonso S; de la Calle VG; García-Sanz R; Gazi L; Opio S; Jiménez M; San-Miguel JF; Mateos MV
    Haematologica; 2015 Jul; 100(7):e289-91. PubMed ID: 25795720
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elotuzumab for the treatment of multiple myeloma.
    Moreau P; Touzeau C
    Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.